Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease

Abstract : Early identification of Alzheimer's disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess. Validated plasma biomarkers would circumvent these challenges. We previously identified the kinase DYRK1A in plasma. To validate DYRK1A as a biomarker for AD diagnosis, we assessed the levels of DYRK1A and the related markers brain-derived neurotrophic factor (BDNF) and homocysteine in two unrelated AD patient cohorts with age-matched controls. Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952, a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile. Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers. These results associate a decreased level of DYRK1A with AD and challenge the use of DYRK1A inhibitors in peripheral tissues as treatment. These measures will be useful for diagnosis purposes.
Liste complète des métadonnées

Littérature citée [52 références]  Voir  Masquer  Télécharger
Contributeur : Gestionnaire Hal-Upmc <>
Soumis le : mercredi 5 juillet 2017 - 16:03:49
Dernière modification le : samedi 31 mars 2018 - 01:15:59


Publication financée par une institution


Distributed under a Creative Commons Paternité 4.0 International License




N Janel, P Alexopoulos, A Badel, F Lamari, Ac Camproux, et al.. Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease. Translational Psychiatry, 2017, 7, pp.e1154. 〈10.1038/tp.2017.123〉. 〈hal-01556869〉



Consultations de la notice


Téléchargements de fichiers